Edition:
India

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,657.50GBp
18 Apr 2019
Change (% chg)

-46.50 (-2.73%)
Prev Close
1,704.00
Open
1,706.00
Day's High
1,709.00
Day's Low
1,655.50
Volume
447,184
Avg. Vol
483,007
52-wk High
2,089.00
52-wk Low
1,183.35

Latest Key Developments (Source: Significant Developments)

Hikma Pharmaceuticals Reports 7 Pct Rise In FY Group Revenue
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA PHARMACEUTICAL - FINAL RESULTS.HIKMA PHARMACEUTICALS PLC - FY GROUP CORE REVENUE OF $2,076 MILLION, UP 7%.HIKMA PHARMACEUTICALS PLC - FY GROUP CORE OPERATING PROFIT OF $460 MILLION, UP 19%.HIKMA PHARMACEUTICALS PLC - FY GROUP REVENUE OF $2,070 MILLION, UP 7%.HIKMA PHARMACEUTICALS PLC - FY GROUP OPERATING PROFIT OF $371 MILLION.HIKMA PHARMACEUTICALS PLC - PROPOSED FULL YEAR DIVIDEND OF 38 CENTS PER SHARE, UP FROM 34 CENTS PER SHARE.HIKMA PHARMACEUTICALS PLC - STRONG PERFORMANCE IN 2018, WITH REVENUE AND PROFITABILITY SIGNIFICANTLY AHEAD OF OUR EXPECTATIONS AT START OF YEAR.HIKMA PHARMACEUTICALS PLC - INJECTABLES BUSINESS CONTINUED TO PERFORM VERY WELL.HIKMA PHARMACEUTICALS PLC - IN 2018 GLOBAL INJECTABLES CORE REVENUE UP 7% TO $832 MILLION (2017: $776 MILLION).HIKMA PHARMACEUTICALS PLC - IN 2019, WE EXPECT GLOBAL INJECTABLES REVENUE TO BE IN RANGE OF $850 MILLION TO $900 MILLION.HIKMA PHARMACEUTICALS PLC - EXPECT REVENUE GROWTH FROM NEW PRODUCT LAUNCHES AND GOOD DEMAND FOR OUR IN-MARKET PORTFOLIO IN INJECTABLES IN 2019.HIKMA PHARMACEUTICALS PLC - IN 2018 GENERICS REVENUE GREW 13% TO $692 MILLION (2017: $615 MILLION).HIKMA PHARMACEUTICALS PLC - WE EXPECT GENERICS REVENUE TO BE IN RANGE OF $650 MILLION TO $700 MILLION IN 2019.HIKMA PHARMACEUTICALS PLC - IN 2019 EXPECT INJECTABLES CORE OPERATING MARGIN TO BE IN RANGE OF 35% TO 38%.  Full Article

Hikma Pharmaceutical Signs Injectable Licensing Agreement With Hansoh Pharmaceutical
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA PHARMACEUTICAL- HIKMA ANNOUNCES INJECTABLE LICENSING AGREEMENT.HIKMA PHARMACEUTICALS PLC - ANNOUNCED A FIVE-YEAR LICENSING AND SUPPLY AGREEMENT WITH HANSOH PHARMACEUTICAL GROUP CO., LTD.HIKMA - AGREEMENT PROVIDES HIKMA WITH EXCLUSIVE RIGHTS TO MARKET A SUITE OF HANSOH'S INJECTABLE ONCOLOGY MEDICINES WITHIN US FOR NEXT FIVE YEARS.HIKMA PHARMACEUTICALS PLC - HANSOH EXPECTS TO FILE THESE PRODUCTS FOR APPROVAL WITH FDA WITHIN NEXT 12 MONTHS.  Full Article

Hikma Raises FY Rev Foreast For Injectables Business
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Hikma Pharmaceuticals PLC ::IN MENA, OUR BRANDED BUSINESS IS CONTINUING TO GROW STEADILY AND WE REMAIN ON TRACK TO MEET OUR FULL YEAR GUIDANCE.ARE RAISING OUR 2018 GUIDANCE AND NOW EXPECT INJECTABLES REVENUE TO BE IN RANGE OF $825 MILLION TO $850 MILLION.SEES CORE INJECTABLES OPERATING MARGIN FOR FY TO BE BETWEEN 39% AND 40%.  Full Article

Hikma Pharmaceuticals Says US Subsidiary Launches Dexrazoxane For Injection
Friday, 20 Apr 2018 

April 20 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA LAUNCHES DEXRAZOXANE FOR INJECTION.US SUBSIDIARY WEST-WARD PHARMACEUTICALS, LAUNCHED DEXRAZOXANE FOR INJECTION, 250MG AND 500MG VIALS, GENERIC EQUIVALENT TO ZINECARD.  Full Article

Hikma Pharmaceuticals CFO Says Expects 2018 Revenue In Range Of $1.85-$2 Bln
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Hikma Pharmaceuticals Plc ::HIKMA PHARMACEUTICALS CFO SAYS EXPECTS 2018 REVENUE IN THE RANGE OF $1.85 BILLION TO CLOSE TO $2 BILLION ‍​.HIKMA PHARMACEUTICALS EXECUTIVE CHAIRMAN SAYS EXPECTS HIGH LEVEL OF PRICE EROSION IN U.S. GENERICS MARKET TO CONTINUE INTO 2018‍​.HIKMA PHARMACEUTICALS CFO SAYS EXPECTS 2018 CAPITAL EXPENDITURE IN THE RANGE OF $120 MILLION TO $140 MILLION.HIKMA PHARMACEUTICALS CFO SAYS CONSOLIDATATION OF MANUFACTURING OPERATIONS IN U.S WOULD RESULT IN ANOTHER 200 JOB CUTS.  Full Article

Hikma Gets U.S. FDA Response On ANDA For Generic Version Of GSK's Advair Diskus
Monday, 12 Mar 2018 

March 12 (Reuters) - Hikma Pharmaceuticals Plc ::UPDATE STATUS ON ANDA FOR GENERIC ADVAIR DISKUS.HAS RECEIVED A RESPONSE FROM U.S. FDA IN RELATION TO ITS ANDA FOR ITS GENERIC VERSION OF GLAXOSMITHKLINE'S ADVAIR DISKUS.REMAINED OUTSTANDING ISSUE REGARDING CLINICAL ENDPOINT STUDY, IN RESPONSE, DECIDED TO ENGAGE IN FDA'S DISPUTE RESOLUTION PROCESS​.HIKMA HAS ALREADY FINALISED PLANNING OF A NEW CLINICAL STUDY AND EXPECTS TO START PATIENT ENROLMENT IN COMING WEEKS.‍HIKMA ANTICIPATES BEING ABLE TO SUBMIT A RESPONSE TO FDA WITH NEW CLINICAL DATA AS EARLY AS POSSIBLE IN 2019​.  Full Article

Hikma Pharmaceutical Names Sigurdur Olafsson As CEO
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Hikma Pharmaceuticals Plc ::SIGURDUR OLAFSSON APPOINTED CEO OF HIKMA.SAYS OLAFSSON WILL ALSO JOIN HIKMA'S BOARD OF DIRECTORS AS AN EXECUTIVE DIRECTOR.SAYS SAID DARWAZAH, HIKMA'S CURRENT CHAIRMAN AND CEO, WILL ASSUME POSITION OF EXECUTIVE CHAIRMAN.SAYS THESE CHANGES ARE EFFECTIVE IMMEDIATELY.  Full Article

Hikma Pharmaceuticals says ‍continue to expect FY revenue around $2.0 bln​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - HIKMA PHARMACEUTICALS PLC ::‍CONTINUE TO EXPECT FULL YEAR REVENUE TO BE AROUND $2.0 BILLION IN CONSTANT CURRENCY IN 2017​.FOR FULL YEAR ‍CONTINUE TO EXPECT GLOBAL INJECTABLES REVENUE TO BE AROUND $775 MILLION, WITH A VERY STRONG CORE OPERATING MARGIN OF AROUND 39%​.‍EXPECT GENERICS REVENUE TO BE AROUND $600 MILLION FOR FULL YEAR AND CORE OPERATING MARGIN TO BE IN LOW SINGLE-DIGITS​.‍REITERATING EXPECTATION FOR BRANDED REVENUE GROWTH IN MID-SINGLE DIGITS IN CONSTANT CURRENCY IN 2017​.  Full Article

Vectura Group posts HY revenue of 78.8 million pounds
Wednesday, 6 Sep 2017 

Sept 6 (Reuters) - Vectura Group Plc :H1 PRETAX LOSS 44.5 MILLION STG.HY REVENUE 78.8 MILLION POUNDS VERSUS 73.9 MILLION POUNDS A YEAR AGO.HY RECURRING REVENUE PERCENT OF TOTAL REVENUE 90.1 PERCENT VERSUS 76.2 PERCENT A YEAR AGO.HY RECURRING REVENUE 71 MILLION POUNDS VERSUS 56.3 MILLION POUNDS A YEAR AGO.DETAILED REVIEW OF PRIORITIES FOR RESEARCH AND DEVELOPMENT PROGRAMMES IN 2017 UNDERTAKEN AND EXPENDITURE FOR FY IS NOW EXPECTED TO BE LOWER, AT £60 MILLION - £70 MILLION."SINCE CRL, VECTURA SUPPORTED HIKMA IN CONSTRUCTIVE DIALOGUE WITH FDA AND A NUMBER OF QUESTIONS RAISED HAVE NOW BEEN CLARIFIED AND RESOLVED"."EXPECTS TO BE ABLE TO CONFIRM REGULATORY TIMETABLE BEFORE END OF 2017".IN LINE WITH BOARD'S EXPECTATIONS, REMAINS ON TRACK TO DELIVER ORIGINAL £10 MILLION TARGET ANNUAL COST SYNERGIES BY 2018 WITH MAJORITY REALISED IN 2017.FURTHER ANNUAL NON-HEADCOUNT COST SYNERGY OPPORTUNITIES OF £1 MILLION - £2 MILLION FROM 2018 HAVE BEEN IDENTIFIED."THERE IS PRODUCTIVE DIALOGUE AND PROGRESS BEING MADE WITH FDA FOLLOWING RECEIPT OF MAJOR CRL FOR VR315 ADVAIR GENERIC IN US, CONCLUDING NUMBER OF OPEN QUESTIONS" - CEO.MAINTAINS PREVIOUS GUIDANCE OF £65 MILLION - £75 MILLION ANNUAL RESEARCH AND DEVELOPMENT EXPENDITURE FOR 2018.  Full Article

Hikma says focused on cost reduction across generics business
Thursday, 17 Aug 2017 

Aug 17 (Reuters) - Hikma Pharmaceuticals Plc ::HIKMA PHARMACEUTICALS PLC SAYS COMPANY IS FOCUSED ON COST REDUCTION ACROSS ALL AREAS OF GENERICS BUSINESS - COMPANY EXEC.HIKMA PHARMACEUTICALS PLC SAYS IN GENERICS BUSINESS, NEGOTIATED SAVINGS WITH SUPPLIERS, THIRD PARTY VENDORS, INCLUDING LAW-FIRMS - COMPANY EXEC.  Full Article

UPDATE 1-Hikma guides for injectables growth after profit surge

March 13 Hikma Pharmaceuticals Plc on Wednesday forecast growth in 2019 for its injectable drugs division, as strong demand along with a rebound in its generics business helped it post a 19 percent jump in full-year core operating profit.